Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
Short course preoperative nivolumab with or without relatlimab showed encouraging efficacy and survival outcomes, which compare favorably with chemo-immunotherapy-based perioperative treatment regimens.
Authors
- Karin Pat
- K. Hartemink (ORCID: https://orcid.org/0000-0001-8951-6430)
- Brigitte Maes (ORCID: https://orcid.org/0009-0004-2301-3370)
- Michel Vanbockrijck
- Dirk Theegarten
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Servet Bölükbas (ORCID: https://orcid.org/0000-0001-8275-5957)
- Paul Baas (ORCID: https://orcid.org/0000-0001-7018-9556)
- Fabian Doerr (ORCID: https://orcid.org/0000-0002-0878-0406)
- Kristof Cuppens (ORCID: https://orcid.org/0000-0002-8153-0008)
- Marcel Wiesweg (ORCID: https://orcid.org/0000-0002-9698-9559)
- Clemens Aigner (ORCID: https://orcid.org/0000-0002-7787-991X)
- Bert Du Pont
- Till Ploenes
Institutions
- Dutch Cancer Society (NL)
- Leiden University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Ruhrlandklinik (DE)
- Jessa Hospital (BE)
- Oncode Institute (NL)
- National Center for Tumor Diseases (DE)
- Essen University Hospital (DE)
- West German Heart and Vascular Center Essen (DE)
- University Hospital Carl Gustav Carus (DE)
- Hasselt University (BE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.ejca.2025.116165
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00